A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors.

[1]  Jamie Fong,et al.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Xiaochun Sun,et al.  Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer , 2005, Molecular Pharmacology.

[3]  David J. Daniels,et al.  A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. , 2004, Journal of medicinal chemistry.

[4]  David J. Daniels,et al.  A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ Heterodimers , 2004 .

[5]  P. Portoghese,et al.  Identity of the putative δ1-opioid receptor as a δ–κ heteromer in the mouse spinal cord , 2003 .

[6]  B. O'dowd,et al.  Oligomerization of opioid receptors: generation of novel signaling units. , 2002, Current opinion in pharmacology.

[7]  L. Devi,et al.  G-protein-coupled receptor dimerization: modulation of receptor function. , 2001, Pharmacology & therapeutics.

[8]  D. Filliol,et al.  Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. , 2001, European journal of pharmacology.

[9]  P. Portoghese,et al.  5'-Guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist , 2000 .

[10]  Lakshmi A. Devi,et al.  G-protein-coupled receptor heterodimerization modulates receptor function , 1999, Nature.

[11]  P B Bradley,et al.  International Union of Pharmacology. XII. Classification of opioid receptors. , 1996, Pharmacological reviews.

[12]  D. L. Larson,et al.  Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. , 1986, Journal of medicinal chemistry.

[13]  D. L. Larson,et al.  Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers. , 1986, Journal of medicinal chemistry.

[14]  J. Mccall,et al.  [3H]U-69593 a highly selective ligand for the opioid κ receptor , 1985 .

[15]  D. L. Larson,et al.  Opioid agonist and antagonist bivalent ligands as receptor probes. , 1982, Life sciences.

[16]  P. Portoghese,et al.  Narcotic antagonistic potency of bivalent ligands which contain .beta.-naltrexamine. Evidence for simultaneous occupation of proximal recognition sites , 1982 .

[17]  B. Morgan,et al.  Analogues of β-LPH61–64 posessing selective agonist activity at μ-opiate receptors , 1981 .

[18]  P. Portoghese,et al.  Stereospecific synthesis of the 6.alpha.- and 6.beta.-amino derivatives of naltrexone and oxymorphone , 1980 .

[19]  Michel Bouvier,et al.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.

[20]  D. L. Larson,et al.  Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. , 1985, Journal of medicinal chemistry.